Image: Pexels | Written by: Medical Companion Travel Content Team
Original articles, please do not reprint without permission
Multiple myeloma is a blood tumor caused by the cancer of plasma cells in the bone marrow. Cancerous plasma cells continue to proliferate in the bone marrow, which not only affects the production of normal red blood cells and white blood cells, but also causes abnormal antibodies to accumulate excessively in the body. Patients often present with symptoms such as bone pain, nausea, loss of appetite, frequent infections, and anemia.
With the continuous development of medical technology, there are now a variety of drugs for the treatment of multiple myeloma have been successfully developed, and darrituliumab is one of them. The drug is currently the first and only subcutaneously injectable anti-CD38 monoclonal antibody combined with pomardomide and dexamethasone.
Therapeutic effect of darrituliumab
APOLLO is an ongoing multicenter, Phase 3, randomized, open-label study that compares daratumumab plus pommalumab and low-dose dexamethasone (D-Pd regimen) with Pd regimen monotherapy in patients with relapsed/refractory multiple myeloma.
The trial results showed that daratumumab combination therapy significantly reduced the risk of disease progression or death by 37% compared with the Pd regimen, achieving the primary endpoint of improving progression-free survival.
The median progression-free survival (PFS) was 12.4 months in the Daratumumab combination treatment group and 6.9 months in the Pd treatment group, and the overall response rate in the daratumumab treatment group was 69% and in the Pd treatment group. Patients treated with Daratumumab show a negative state of tiny residual lesions.
epilogue
It can be seen that daratumumab can prolong the survival of patients, reduce the risk of death, improve remission rate, improve the quality of life and disease progression of patients, and treat multiple myeloma with significant effects. The listing of this drug has brought new treatment options and options to patients with multiple myeloma.